Ok_老虎社区_美港股上老虎

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":605957478,"tweetId":"605957478","gmtCreate":1639105059805,"gmtModify":1639106292443,"author":{"id":3555327015224476,"idStr":"3555327015224476","authorId":3555327015224476,"authorIdStr":"3555327015224476","name":"rustic","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":18,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Ok</p></body></html>","htmlText":"<html><head></head><body><p>Ok</p></body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/605957478","repostId":1118435301,"repostType":4,"repost":{"id":"1118435301","pubTimestamp":1639104912,"share":"https://www.laohu8.com/m/news/1118435301?lang=&edition=full","pubTime":"2021-12-10 10:55","market":"hk","language":"en","title":"Chinese Drugmaker Asymchem Slips in Hong Kong Trading Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=1118435301","media":"Bloomberg","summary":"(Bloomberg) -- Chinese contract drug manufacturer Asymchem Laboratories Tianjin Co. dropped in its f","content":"<p>(Bloomberg) -- Chinese contract drug manufacturer Asymchem Laboratories Tianjin Co. dropped in its first day of trading in Hong Kong, after completing the Asian financial hub’s biggest initial public offering in more than two months.</p>\n<p>The shares fell as much as 4.5% to HK$370.40 on Friday. They were sold at HK$388 apiece in an IPO that raised about HK$7.15 billion ($917 million). The H-shares had been marketed at between HK$350 and HK$410 and were ultimately priced at a discount of 34% to Asymchem’s Shenzhen-listed stock.</p>\n<p>Asymchem is the largest IPO in Hong Kong since Dongguan Rural Commercial Bank Co.’s $1.2 billion deal in September. Hong Kong’s exchange has hosted few large offerings in recent months as Beijing’s clampdowns on various industries soured sentiment in both the primary and secondary markets.</p>\n<p>Twelve of 16 IPOs in the city since August raising over $100 million each ended their first session below their listing price, according to data compiled by Bloomberg as of Thursday.</p>\n<p>Asymchem, a Tianjin-based contract development and manufacturing organization (CDMO) for the drug industry, plans to use proceeds to add capacity and capabilities as well as increase market share. Goldman Sachs Group Inc. and Citic Securities Co. were joint sponsors for the share sale.</p>\n<p>Two other smaller debuts in Hong Kong on Friday had mixed performance. Gushengtang Holdings Ltd., a traditional Chinese medicine healthcare service provider, jumped as much as 18% following a $104 million offering. CANbridge Pharmaceuticals Inc., a biopharmaceutical company, dropped as much as 29% following an $88 million IPO.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Drugmaker Asymchem Slips in Hong Kong Trading Debut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Drugmaker Asymchem Slips in Hong Kong Trading Debut\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-10 10:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/chinese-drugmaker-asymchem-slips-hong-020055996.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Chinese contract drug manufacturer Asymchem Laboratories Tianjin Co. dropped in its first day of trading in Hong Kong, after completing the Asian financial hub’s biggest initial public ...</p>\n\n<a href=\"https://finance.yahoo.com/news/chinese-drugmaker-asymchem-slips-hong-020055996.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"06821":"凯莱英"},"source_url":"https://finance.yahoo.com/news/chinese-drugmaker-asymchem-slips-hong-020055996.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118435301","content_text":"(Bloomberg) -- Chinese contract drug manufacturer Asymchem Laboratories Tianjin Co. dropped in its first day of trading in Hong Kong, after completing the Asian financial hub’s biggest initial public offering in more than two months.\nThe shares fell as much as 4.5% to HK$370.40 on Friday. They were sold at HK$388 apiece in an IPO that raised about HK$7.15 billion ($917 million). The H-shares had been marketed at between HK$350 and HK$410 and were ultimately priced at a discount of 34% to Asymchem’s Shenzhen-listed stock.\nAsymchem is the largest IPO in Hong Kong since Dongguan Rural Commercial Bank Co.’s $1.2 billion deal in September. Hong Kong’s exchange has hosted few large offerings in recent months as Beijing’s clampdowns on various industries soured sentiment in both the primary and secondary markets.\nTwelve of 16 IPOs in the city since August raising over $100 million each ended their first session below their listing price, according to data compiled by Bloomberg as of Thursday.\nAsymchem, a Tianjin-based contract development and manufacturing organization (CDMO) for the drug industry, plans to use proceeds to add capacity and capabilities as well as increase market share. Goldman Sachs Group Inc. and Citic Securities Co. were joint sponsors for the share sale.\nTwo other smaller debuts in Hong Kong on Friday had mixed performance. Gushengtang Holdings Ltd., a traditional Chinese medicine healthcare service provider, jumped as much as 18% following a $104 million offering. CANbridge Pharmaceuticals Inc., a biopharmaceutical company, dropped as much as 29% following an $88 million IPO.","news_type":1},"isVote":1,"tweetType":1,"viewCount":75,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/605957478"}